Search results
19 wrz 2024 · Read the new ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The updated management guidelines aim to: Allow for a more complete and precise estimation of risk
- Online Terms and Conditions
American Society for Colposcopy and Cervical Pathology...
- Online Terms and Conditions
Updated US consensus guidelines for management of cervical screening abnormalities are needed to accommodate the 3 available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cervical cytology, and cer-vical cytology alone.
The tables presented here display the risk estimates of CIN 3+, as well as CIN 2+ and cancer for every possible combinations of test result as the data permits. These risk scores are obtained at time points, 0 (immediate), 1, 2, 3, 4, and 5 years.
An interactive Excel model that evaluates the trade-offs of four cervical cancer screening approaches and five cervical precancer treatment scenarios, looking at number of women reached, effectiveness of approach, and associated costs.
Guidelines Overview. Links and resources related to cervical screening, management, and colposcopy guidelines and recommendations. Screening Guidelines. Screening recommendations for the identification of precursors and prevention of cervical cancer. View Screening Guidelines. Management Guidelines & the Enduring Guidelines Process.
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
Links and resources related to cervical screening, management, and colposcopy guidelines and recommendations.
